A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs ARRY 797 (Primary)
- Indications Dilated cardiomyopathy
- Focus Registrational; Therapeutic Use
- Sponsors Array BioPharma
- 31 Aug 2018 Biomarkers information updated
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.
- 06 Feb 2018 According to an Array BioPharma media release, this trial is expected to begin in this quarter.